2011年1月20〜22日に米国サンフランシスコにて開催された2011年 消化器癌シンポジウム(2011 Gastrointestinal Cancers
Symposium)より、大腸癌や胃癌などの注目演題のレポートをお届けします。
演題レポートの冒頭には “Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
演題レポートの冒頭には “Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
2011年2月10日 サイトをアップしました。
|
A Randomized Phase II Study of PEP02, Irinotecan, or Docetaxel as a Second Line Therapy in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PEP0206).
David Cunningham, et al. |
|
Randomized phase III study of S-1 alone versus S-1 + docetaxel in the treatment for advanced gastric cancer (The START trial)
Yeul Hong Kim, et al. |
|
EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer.
Alice Dewdney, et al. |
|
A Randomized, Phase 1/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab vs Panitumumab Alone in Patients With Wild-Type KRAS Metastatic Colorectal Cancer (mCRC) : Safety and Efficacy Result.
Eric Van Cutsem, et al. |
|
Chemoradiation with FOLFOX plus Cetuximab in Locally Advanced Cardia or Esophageal cancer. Final Results of a GERCOR phase II Trial (ERaFOX).
Aimery de Gramont, et al. |
|
AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 vs. FOLFOX4 alone as adjuvant treatment for colon cancer.
Aimery de Gramont, et al. |
|
Adjuvant FOLFIRI + Cetuximab in Patients with Resected Stage III Colon Cancer - NCCTG Intergroup phase III trial N0147.
Jocelin Huang, et al. |
|
A Single Arm Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer.
Raymond Wadlow, et al. |
|
Clinipathological features in metastatic colorectal cancer patients with KRAS wild type versus codon 12 and codon 13 mutant: Results from a multicenter, cross-sectional study by the Japan Study Group of KRAS Mutation in Colorectal Cancer.
Takayuki Yoshino, et al.
Clinical outcome in patients with metastatic colorectal cancer harboring p.G13D KRAS mutation treated with Cetuximab.
Hideaki Bando, et al.
|
|
Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial.
Hubert Piessevaux, et al. |
|
Pooled Safety Results from SPIRITT: A Multicenter, Open-label, Randomized, Phase 2 Study of FOLFIRI with Panitumumab or Bevacizumab as 2nd-line Treatment in Patients with Metastatic Colorectal Cancer (mCRC)
J. Randolph Hecht, et al. |
